ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

KRTX Karuna Therapeutics Inc

329.83
0.00 (0.00%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Karuna Therapeutics Inc KRTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 329.83 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
329.83 329.83
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/3/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202416:01EDGAR2Form 144 - Report of proposed sale of securities
01/3/202405:02EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01/3/202405:01EDGAR2Form 8-K - Current report
22/2/202405:39EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202405:32EDGAR2Form 8-K - Current report
22/2/202405:30BWKaruna Therapeutics Reports Fourth Quarter and Full Year..
15/2/202415:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202409:04EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202416:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202410:56EDGAR2Form 144 - Report of proposed sale of securities
05/2/202415:12EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
22/1/202405:05EDGAR2Form PREM14A - Preliminary proxy statements relating to..
16/1/202415:18EDGAR2Form 8-K - Current report
09/1/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:18EDGAR2Form 144 - Report of proposed sale of securities
08/1/202409:06PRNUSKuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to..
29/12/202315:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202316:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202316:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202316:07EDGAR2Form 8-K - Current report
22/12/202315:28EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202315:22EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202315:12EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202314:30PRNUSALERT: Rowley Law PLLC is Investigating Proposed Acquisition..
22/12/202310:15DJNTrending: Bristol Myers to Buy Karuna Therapeutics for $14..
22/12/202307:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202307:26EDGAR2Form 8-K - Current report
22/12/202306:05BWBristol Myers Squibb Strengthens Neuroscience Portfolio with..
22/12/202305:59BWBristol Myers Squibb Strengthens Neuroscience Portfolio with..
14/12/202317:30BWKaruna Therapeutics Announces The Lancet Publication of Data..
12/12/202315:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202314:24EDGAR2Form 144 - Report of proposed sale of securities
29/11/202309:17BWPureTech Founded Entity Karuna Therapeutics Announces U.S...
29/11/202306:13DJNKaruna Therapeutics Gets FDA Acceptance for KarXT NDA
29/11/202305:30BWKaruna Therapeutics Announces U.S. Food and Drug..
16/11/202315:01BWKaruna Therapeutics Announces Positive Results from Phase 1b..
13/11/202316:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202315:25EDGAR2Form 144 - Report of proposed sale of securities
02/11/202305:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202305:36EDGAR2Form 8-K - Current report
02/11/202305:30BWKaruna Therapeutics Reports Third Quarter 2023 Financial..
01/11/202305:45BWKaruna Therapeutics to Present Data from the EMERGENT..
01/11/202305:30BWKaruna Therapeutics to Present at Upcoming Investor..
19/10/202305:30BWKaruna Therapeutics to Announce Third Quarter 2023 Financial..
10/10/202315:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

Delayed Upgrade Clock